12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Belviq lorcaserin regulatory update

FDA approved an NDA from Arena for Belviq lorcaserin for chronic weight management. The agency recommended the U.S. Drug Enforcement Administration classify Belviq as a class IV scheduled drug, where class I indicates the highest potential for abuse and class V the lowest. Arena and marketing partner Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan) said the pharma will announce a launch timeline for Belviq after the DEA completes its review of the drug, which Arena estimates will take 4-6 months. The pharma has not...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >